The NeurologyLive® clinical focus page on sleep disorders provides information about the latest FDA actions, clinical guideline updates, clinical trial findings, and interviews with physicians on conditions such as obstructive sleep apnea, cataplexy, narcolepsy, insomnia, excessive daytime sleepiness, and more. The page features podcasts, videos, and news stories about the latest in clinical care for these sleep disorders.
July 22nd 2024
Here's some of what is coming soon to NeurologyLive® this week.
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, ...
September 16, 2024
Register Now!
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
October 16, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Reena Mehra, MD, MS: Importance of Screening for Obstructive Sleep Apnea
October 11th 2019The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed the importance of identifying and diagnosing obstructive sleep apnea as a prevention for a number of its consequential risk factors.
Reena Mehra, MD, MS: Early Diagnosis of OSA
October 10th 2019The director of the Sleep Disorders Research Program at Cleveland Clinic Lerner College of Medicine discussed the importance of identifying and diagnosing obstructive sleep apnea as a prevention for a number of its consequential risk factors.
Lemborexant Proves Safe, Effective for Insomnia in Long-Term Phase 3 Study
September 30th 2019Year-long data presented at World Sleep 2019 suggest that Eisai’s lemborexant is safe and effective in treating adults with insomnia, supporting its recently submitted NDA. It is set to be reviewed by the FDA by late December.
JZP-258 Shows Success In Stabilizing Cataplexy for Patients With Narcolepsy
September 28th 2019Data presented at World Sleep 2019 has suggested that the investigation Jazz Pharmaceuticals sodium oxybate agent, JZP-258, is efficacious and safe in treating patients with narcolepsy who have cataplexy.
Pitolisant Offers Important Risk-Benefit Profile for Patients With Narcolepsy
August 23rd 2019Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.
The Symbiotic Relationship of Artificial Intelligence and Neurology
August 18th 2019The associate chief of the MS division and professor of neurology at the University of Pennsylvania described the relationship between artificial intelligence and medicine, and how he sees it evolving in the future.
Pitolisant Offers Important Risk-Benefit Profile for Patients With Narcolepsy
August 16th 2019Jeffrey Dayno, MD, chief medical officer of Harmony Biosciences, as well as John C. Jacobs, the chairman and CEO, shared their insight into the potential impact pitolisant can make in the treatment of narcolepsy and excessive daytime sleepiness.
Pitolisant Approved for Excessive Daytime Sleepiness in Narcolepsy
August 15th 2019With its FDA approval, the selective histamine 3 receptor antagonist/inverse agonist, branded Wakix, is the first and only therapy for narcolepsy which is not scheduled as a controlled substance by the DEA. It is expected to enter the market by Q4 2019.
Idiopathic REM Sleep Behavior Disorder Distinct From Narcolepsy-Associated Pathophysiology
August 8th 2019New study findings confirm that idiopathic rapid‐eye‐movements sleep behavior disorder and RBD secondary to narcolepsy type 1 can be identified via video‐polysomnography and skin biopsy for phosphorylated α‐synuclein deposits.
Can Telemedicine Make a Difference in Neurology Subspecialties?
August 5th 2019The staff neurologist at Cleveland Clinic’s Mellen Center for MS shared her insight into the use of telemedicine in an outpatient setting across a number of subspecialties in neurology and how it can supplement care going forward.